Kala Pharmaceuticals, Inc. (KALA)
USD 3.75
(0.81%)
USD 3.75
(0.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -39.15 Million USD | 51.87% |
| 2022 | -81.35 Million USD | 25.66% |
| 2021 | -109.43 Million USD | -13.72% |
| 2020 | -96.23 Million USD | -9.08% |
| 2019 | -88.22 Million USD | -36.31% |
| 2018 | -64.72 Million USD | -62.31% |
| 2017 | -39.87 Million USD | -22.06% |
| 2016 | -32.66 Million USD | -104.87% |
| 2015 | -15.94 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -9.63 Million USD | 18.42% |
| 2024 Q1 | -11.77 Million USD | -26.04% |
| 2023 Q4 | -9.34 Million USD | -6.61% |
| 2023 FY | -39.15 Million USD | 51.87% |
| 2023 Q1 | -11.68 Million USD | -13.97% |
| 2023 Q2 | -9.59 Million USD | 17.84% |
| 2023 Q3 | -8.76 Million USD | 8.72% |
| 2022 Q4 | -10.25 Million USD | 29.64% |
| 2022 FY | -81.35 Million USD | 25.66% |
| 2022 Q2 | -26.82 Million USD | 13.07% |
| 2022 Q3 | -14.56 Million USD | 45.68% |
| 2022 Q1 | -30.85 Million USD | 34.1% |
| 2021 Q1 | -28.31 Million USD | 2.31% |
| 2021 Q3 | -26.07 Million USD | 10.24% |
| 2021 Q4 | -46.81 Million USD | -79.57% |
| 2021 FY | -109.43 Million USD | -13.72% |
| 2021 Q2 | -29.04 Million USD | -2.58% |
| 2020 FY | -96.23 Million USD | -9.08% |
| 2020 Q4 | -28.98 Million USD | -12.16% |
| 2020 Q3 | -25.84 Million USD | -21.44% |
| 2020 Q2 | -21.28 Million USD | -5.74% |
| 2020 Q1 | -20.12 Million USD | 0.36% |
| 2019 Q3 | -21.56 Million USD | 3.76% |
| 2019 Q2 | -22.41 Million USD | 6.82% |
| 2019 Q1 | -24.05 Million USD | -2.05% |
| 2019 FY | -88.22 Million USD | -36.31% |
| 2019 Q4 | -20.19 Million USD | 6.35% |
| 2018 Q2 | -14.51 Million USD | -30.34% |
| 2018 Q3 | -15.49 Million USD | -6.73% |
| 2018 FY | -64.72 Million USD | -62.31% |
| 2018 Q1 | -11.13 Million USD | 0.01% |
| 2018 Q4 | -23.56 Million USD | -52.09% |
| 2017 Q4 | -11.14 Million USD | -16.84% |
| 2017 Q1 | -9.57 Million USD | -16.78% |
| 2017 Q2 | -9.63 Million USD | -0.62% |
| 2017 Q3 | -9.53 Million USD | 1.0% |
| 2017 FY | -39.87 Million USD | -22.06% |
| 2016 Q4 | -8.19 Million USD | 15.91% |
| 2016 Q2 | -9.65 Million USD | -90.11% |
| 2016 FY | -32.66 Million USD | -104.87% |
| 2016 Q1 | -5.07 Million USD | 0.0% |
| 2016 Q3 | -9.74 Million USD | -1.01% |
| 2015 FY | -15.94 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 183.356% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -159.257% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 123.45% |
| Cosmos Health Inc. | -21.83 Million USD | -79.344% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -95.276% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 74.831% |
| Cronos Group Inc. | -81.37 Million USD | 51.886% |
| Incannex Healthcare Limited | -30.04 Million USD | -30.332% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 519.601% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -726.584% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -718.193% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -718.193% |
| SCYNEXIS, Inc. | 72.66 Million USD | 153.879% |
| Safety Shot Inc | -12.18 Million USD | -221.344% |
| Theratechnologies Inc. | -10.62 Million USD | -268.429% |
| Alpha Teknova, Inc. | -35.56 Million USD | -10.095% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -1010.165% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 144.657% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -732.865% |
| Dynavax Technologies Corporation | -37.02 Million USD | -5.739% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 118.73% |
| Radius Health, Inc. | -3.92 Million USD | -897.529% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1456.645% |
| Alvotech | -354.86 Million USD | 88.967% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 75.434% |
| SIGA Technologies, Inc. | 83.62 Million USD | 146.822% |
| Shineco, Inc. | -17.06 Million USD | -129.423% |
| Silver Spike Investment Corp. | 7.34 Million USD | 633.412% |
| Journey Medical Corporation | -2.07 Million USD | -1788.712% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -187.523% |
| Embecta Corp. | 221.5 Million USD | 117.676% |
| Harrow Health, Inc. | 580 Thousand USD | 6850.517% |
| Procaps Group, S.A. | 38.97 Million USD | 200.462% |
| Biofrontera Inc. | -22.67 Million USD | -72.655% |
| DURECT Corporation | -36.88 Million USD | -6.152% |
| PainReform Ltd. | -9.58 Million USD | -308.525% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -643.082% |
| OptiNose, Inc. | -22.74 Million USD | -72.116% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 409.951% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 412.599% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -530.4% |
| ProPhase Labs, Inc. | -21.61 Million USD | -81.155% |
| Phibro Animal Health Corporation | 53.31 Million USD | 173.437% |
| Procaps Group S.A. | 52.32 Million USD | 174.828% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -359.38% |
| Viatris Inc. | 766.2 Million USD | 105.11% |
| Rockwell Medical, Inc. | -6.67 Million USD | -487.001% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -645.204% |
| Tilray Brands, Inc. | -174.74 Million USD | 77.594% |
| PetIQ, Inc. | 60.01 Million USD | 165.239% |
| Talphera, Inc. | -16.88 Million USD | -131.825% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 115.605% |
| Alimera Sciences, Inc. | -1.47 Million USD | -2561.659% |
| Assertio Holdings, Inc. | -243.53 Million USD | 83.923% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -564.468% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 71.597% |
| Hempacco Co., Inc. | -8.81 Million USD | -344.3% |
| Alvotech | -354.86 Million USD | 88.967% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 110.737% |
| Kamada Ltd. | 10.06 Million USD | 489.04% |
| Currenc Group, Inc. | -6.64 Million USD | -489.14% |
| Indivior PLC | -4 Million USD | -878.825% |
| Evoke Pharma, Inc. | -7.43 Million USD | -426.895% |
| Flora Growth Corp. | -50.35 Million USD | 22.245% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -95.276% |
| Evolus, Inc. | -49.23 Million USD | 20.474% |
| HUTCHMED (China) Limited | 18.37 Million USD | 313.078% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 119.876% |
| Akanda Corp. | -10.05 Million USD | -289.529% |